Objective To observe the vaccination reactions and immunogenicity of the application of lyophilized Vero cell rabies vaccine without adjuvant in a way of low-dose intradermal injection for post-exposure group. Methods Conducting post-exposure immunization for 256 persons with the class Ⅱ level exposure to rabies. Based on a randomized, single-blind principle, all subjects were divided into intradermal injection (ID) group (n= 128),injected 0.1 ml for each site in accordance with 0,3,7,28,90 d,2 sites,2 sites,2sites,1 site,1 site respectively, and intramuscular injection(IM) group(n= 128) in accordance with 0,3,7,14,28 d in full-volume (0.5ml) PVRV Deltoid injection. The local and systemic vaccination reactions were observed for the different injection ways. The indirect sandwich ELISA assay was used to analyze the antibody levels. Results For the intradermal injection group, the incidence rates for local redness and swelling, induration, pain, itch were 1.27%, 0.29% ,0.49% ,11.43% respectively,for the intramuscular group, the incidence rates were 1.09% ,0. 16% ,2. 81% ,1.41% respectively. From the point of systemic reactions,the incidence rates of fever,rash,headache,fatigue and weakness were 0.31 % ,0. 16% ,0. 31 % , 1.09% respectively in the intradermal injection group,and the rates were 0.31% ,0.31% ,0.63% , 1.09% respectively in intramuscular group. All the adverse effects often occurred following the 1st,2nd injection. The seroconversion rates for intradermal injection and intramuscular were 94.53% ,95.31% following 14 d immunization respectively,the rates were 96. 83% ,97.64% following 42 d immunization respectively. For the post-exposure group,no statistical difference in significance was found between the two seroconversion rates. Conclusion For the application of domestic lyophilized Vero cell rabies vaccine,its adverse reactions are mild,and immunogenicity is good.

Objective: To study the interaction between hepatitis B virus X protein(HBx) and mitochondrial elongation factor G1 (EFG1) in yeast cells or hepatoma cells. Methods: After verification the interaction between HBx and EFG1 by CytoTrap yeast two-hybrid system, EFG1 genome was amplified by means of polymerase chain reaction(PCR) and cloned into the pcDNA3.1/myc-His(-)A vector, following verification by sequencing. Expression of HBx and EFG1 protein was verified in Huh7 cells. Then the recombinant vector pcDNA3.1/myc-His(-)A-EFG1 and pFLAG-CMV-2-HBx were transfected into Huh7 cells; 48 h later, the cells were lysed. The direct interaction between HBx and EFG1 was further confirmed by the Co-immunoprecipitation (Co-IP) assay. Results: The interaction between HBx and EFG1 was successfully verified by CytoTrap yeast two-hybrid system. The recombined plasmid pcDNA3.1/myc-His(-)A-EFG1 was obtained. Furthermore, Co-IP assay was used to confirm the interaction between HBx and EFG1 in Huh7 cells. Conclusions The direct interaction between HBx and EFG1 was confirmed. Therefore our findings provide experimental basis for the influence of HBx protein on the expression of mitochondrial protein and provide new insights into the pathogenesis of HBx in the development of hepatocellular carcinoma.